Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An update from OncoSil Medical Ltd ( (AU:OSL) ) is now available.
OncoSil Medical Limited announced that 120 German hospitals are now entitled to negotiate funding for the OncoSil™ device under the innovation funding program, reflecting a 43% increase from the previous year. This progress underscores the growing acceptance of the OncoSil device within the German healthcare system, solidifying its market presence and commitment to improving treatment outcomes for patients with pancreatic cancer.
More about OncoSil Medical Ltd
OncoSil Medical Limited (ASX:OSL) specializes in developing a brachytherapy device, the OncoSil™ device, aimed at treating locally advanced unresectable pancreatic cancer. This device provides targeted intratumoral placement of Phosphorous-32 (32P) and is designed to be used in conjunction with gemcitabine-based chemotherapy. It is recognized as a breakthrough device in the EU, UK, and US and is commercialized in over 30 countries, including initial treatments in Spain, Italy, and Israel.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$27.64M
See more insights into OSL stock on TipRanks’ Stock Analysis page.
